Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis | MicrobiomeTrials← Back to trialsNCT05473520
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-05-24Est. Completion: 2030-01-31
Enrollment target: 150 participants Locations- Hospital Queen Elizabeth I, Kota Kinabalu, Sabah, Malaysia
- Klinik Kesihatan Luyang, Kota Kinabalu, Sabah, Malaysia
- Klinik Kesihatan Menggatal, Kota Kinabalu, Sabah, Malaysia
- Universiti Malaysia Sabah (UMS), Borneo Medical and Health Research Centre, Kota Kinabalu, Sabah, Malaysia
- National University Hospital, Singapore, Singapore, Singapore
- TB Control Unit, Singapore, Singapore
Other microbiome trials you might be interested in
Mycobacterium Abscessus Lung Disease
Background: Mycobacterium abscessus, one of the most common species of nontuberculous mycobacterium (NTM), poses a signi…
Taipei, TaiwanEst. completion Mar 1, 2026
Nontuberculous Mycobacterial Lung Disease
The incidence of nontuberculous mycobacterial lung disease (NTM-LD) is increasing worldwide and in Eastern Asia. NTM-LD …
Taipei, TaiwanEst. completion Dec 1, 2026
Phase 2
TERMINATED
MAC Lung DiseaseTreatment Refractory MAC Lung Disease
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen)…
Birmingham, United StatesCompleted Dec 18, 2024